Age: 53.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Psoriasis
Clinical narrative: diagnosed with acute COVID; diagnosed with acute COVID; developed RLL Pneumonia; Long COVID; cognitive defects in shifting focus, concentration, working memory, immediate memory/inability to do basic math problems; cognitive defects in shifting focus, concentration, working memory, immediate memory; cognitive defects in shifting focus, concentration, working memory, immediate memory; inability to read; Dose 1: Moderna, Dose 2: Pfizer; This is a spontaneous report received from a Physician.  A 56-year-old female patient received BNT162b2 (BNT162B2), on 04Aug2021 as dose 2, single (Lot number: EW0177), in arm and on 11Jan2022 as dose 3 (booster), single (Lot number: FL3198) at the age of 53 years, in arm, all intramuscular for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 23Dec2020 as dose 1, single (Lot number: 011J20A) intramuscular, in arm for covid-19 immunisation. The patient's relevant medical history included: "depression anxiety", start date: 1965 (ongoing); "depression anxiety", start date: 1965 (ongoing); "Hashimoto's thyroiditis" (ongoing); "Rheumatoid arthritis" (ongoing). Concomitant medication(s) included: WELLBUTRIN oral taken for depression (ongoing); EFFEXOR oral taken for depression (ongoing); ROPINIROLE oral taken for depression (ongoing); METHIMAZOLE oral taken for autoimmune thyroiditis, graves' disease (ongoing); SIMPONI intramuscular taken for rheumatoid arthritis (ongoing). The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 04Aug2021, outcome "unknown", described as "Dose 1: Moderna, Dose 2: Pfizer"; POST-ACUTE COVID-19 SYNDROME (disability, medically significant) with onset Jul2022, outcome "not recovered", described as "Long COVID"; DISTURBANCE IN ATTENTION (disability, medically significant), MEMORY IMPAIRMENT (disability, medically significant) all with onset Jul2022, outcome "not recovered" and all described as "cognitive defects in shifting focus, concentration, working memory, immediate memory"; COGNITIVE DISORDER (disability, medically significant) with onset Jul2022, outcome "not recovered", described as "cognitive defects in shifting focus, concentration, working memory, immediate memory/inability to do basic math problems"; COVID-19 PNEUMONIA (medically significant) with onset Jul2022, outcome "recovered", described as "developed RLL Pneumonia"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Jul2022, outcome "unknown" and all described as "diagnosed with acute COVID"; READING DISORDER (disability, medically significant) with onset Jul2022, outcome "not recovered", described as "inability to read". The events "long covid", "cognitive defects in shifting focus, concentration, working memory, immediate memory/inability to do basic math problems", "cognitive defects in shifting focus, concentration, working memory, immediate memory" and "inability to read" required physician office visit. Therapeutic measures were taken as a result of drug ineffective, covid-19, covid-19 pneumonia, post-acute covid-19 syndrome.  Clinical course: The patient was diagnosed with acute COVID in Jul2022 then developed RLL Pneumonia and long Covid. The patient was treated with Paxlovid oral A Alox (antibiotics). RLL Pneumonia resaved. Treatment for long COVID was reported as "Abx: antibiotics for pneumonia". It was reported that long COVID started on Jul2022 (developed after the first COVID infection) and included cognitive defects in shifting focus, concentration, working memory, immediate memory, inability to read and inability to do basic math problems, she was no longer able to work as a pediatrician.; Sender's Comments: Vaccine efficacy varies from person to person and is subject to many other factors. The association between the event lack of effect (COVID-19 and COVID-19 Pneumonia) with BNT162b2 can not be fully excluded. There is no reasonable possibility that the event s post-acute COVID-19 syndrome (Long COVID), cognitive disorder, disturbance in attention, memory impairment, and reading disorder were related to BNT162b2. These are more likely complications of the COVID-19 infection.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-202400226520 Same reporter/patient/vaccine; different dose/event;US-PFIZER INC-202400226522 Same reporter/patient/vaccine; different dose/event;US-PFIZER INC-202400226519 Same reporter/patient/vaccine; different dose/event;US-PFIZER INC-202400226518 Same reporter/patient/vaccine; different dose/event;US-PFIZER INC-202400226517 Same reporter/patient/vaccine; different dose/event;US-PFIZER INC-202400226521 Same reporter/patient/vaccine; different dose/event;